Queen's Health Sciences (QHS) in Canada has announced the launch of a centralised Clinical Trial Support Unit (CTSU).

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

Zura Bio has launched the Phase II TibuSHIELD trial of tibulizumab for moderate to severe hidradenitis suppurativa (HS).

Viridian Therapeutics’ veligrotug has shown one-year durability in a Phase III trial in patients with active thyroid eye ...

KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...

At the Outsourcing in Clinical Trials East Coast 2025 conference in King of Prussia, panelists were asked how trial sponsors ...

Ionis Pharmaceuticals has reported outcomes from the Phase III Essence study of olezarsen in individuals with moderate ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

The FDA in the US has granted clearance to BrainStorm to commence a Phase IIIb trial of its NurOwn therapy for ALS.

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial of ifinatamab ...

The theme for International Clinical Trials Day 2025, set by the Association of Clinical Research Professionals is “Powered by Purpose”.

The progress the UK has made as a global contributor to clinical trials is “remarkable”, says former health minister Lord ...